Cancer News and Research

Latest Cancer News and Research

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.

9 Mar 2010

Positive results from international study of Oncotype DX breast cancer RS

Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.

9 Mar 2010

California venture capitalist/ philanthropist gifts $6M to Institute for Systems Biology

The Institute for Systems Biology, an independent, non-profit biomolecular research institute, has received a $6 million gift from a California venture capitalist and philanthropist to support strategic organizational objectives.

9 Mar 2010

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.

9 Mar 2010

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

The Society for Biomolecular Sciences will honor three researchers for their substantial contributions to the field of drug discovery. Each recipient will accept their award and speak at the SBS 16th Annual Conference & Exhibition in Phoenix, Arizona, April 11-15, 2010.

9 Mar 2010

Research reveals link between repeated anaesthesia and memory impairment

There is a link between repeated anaesthesia in children and memory impairment, though physical activity can help to form new cells that improve memory, reveals new research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

9 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

8 Mar 2010

Response Genetics to raise $4M from private placement of over 3M newly issued shares

Response Genetics, Inc. announced today that it has entered into a purchase agreement with certain new and existing investors and certain funds managed by Lansdowne Partners Limited Partnership to raise approximately $4 million from the private placement of 3,005,349 newly issued shares of its common stock, at a purchase price of $1.31 per share. The signing of the purchase agreement occurred on Friday, March 5, 2010. We expect the final closing of the shares will occur on Monday, March 8, 2010.

8 Mar 2010

Repeated anaesthesia in children linked to memory impairment

8 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions.

8 Mar 2010

MabCure closes private placement, converts bridge loan into equity securities

MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.

8 Mar 2010

Enzon Pharmaceuticals’ outstanding principal balance of 4% convertible notes is now $134.5M

Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.

8 Mar 2010

Genta announces private placement of Convertible Notes for $25M

Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.

8 Mar 2010

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

A drug for treating a group of conditions that affect the bone marrow is unlikely to be made available on the NHS in England and Wales after the body which provides independent advice on treatments said that it is unlikely to be cost-effective.

8 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

Positive results from international study of Oncotype DX breast cancer RS

California venture capitalist/ philanthropist gifts $6M to Institute for Systems Biology

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

Research reveals link between repeated anaesthesia and memory impairment

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Response Genetics to raise $4M from private placement of over 3M newly issued shares

Repeated anaesthesia in children linked to memory impairment

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

MabCure closes private placement, converts bridge loan into equity securities

Enzon Pharmaceuticals’ outstanding principal balance of 4% convertible notes is now $134.5M

Genta announces private placement of Convertible Notes for $25M

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

Cancer Research - Second Edition eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in